Trevi Therapeutics Shares Surge Ahead of Key Clinical Data Release

Trevi Therapeutics has seen its stock demonstrate notable strength in anticipation of upcoming clinical presentations. The biopharmaceutical company’s shares climbed 5.4 percent in a single trading session following its announcement that comprehensive results from its Phase 2a RIVER study for Haduvio will be presented at the European Respiratory Society (ERS) Congress. Over the preceding two-week period, the equity had already advanced by an impressive 11.6 percent.

The upcoming presentation, scheduled for September 28th and 29th in Amsterdam, will feature a detailed breakdown of the drug candidate’s efficacy, safety profile, and responder analyses for treating refractory chronic cough (RCC). These findings follow the release of compelling topline data in March,... Read more...